Lupin Ltd. is Rated Hold by MarketsMOJO

Understanding the Current Rating

The 'Hold' rating assigned to Lupin Ltd. indicates a balanced stance for investors, suggesting that while the stock has solid attributes, it may not currently offer compelling upside relative to its risks. This rating is derived from a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. Each of these factors contributes to the overall assessment of the stock’s investment potential in the Pharmaceuticals & Biotechnology sector.

Quality Assessment

As of 30 September 2026, Lupin Ltd. maintains a good quality grade. The company demonstrates strong operational performance, highlighted by consistent profitability and efficient capital utilisation. Its Return on Capital Employed (ROCE) stands at an impressive 27.06% for the half-year period, signalling effective use of capital to generate earnings. Additionally, the Return on Equity (ROE) is robust at 25.7%, reflecting strong returns for shareholders. The company’s debt-to-equity ratio remains low at 0.11 times, underscoring a conservative capital structure that limits financial risk.

Valuation Perspective

Currently, Lupin Ltd. is rated as having a very attractive valuation. The stock trades at a Price to Book (P/B) ratio of 4.2, which is considered a discount relative to its peers’ historical averages. This valuation is supported by a favourable Price/Earnings to Growth (PEG) ratio of 0.3, indicating that the stock’s price is reasonable in relation to its earnings growth prospects. Despite the midcap status, the company’s valuation metrics suggest that the stock is priced attractively for investors seeking exposure to the pharmaceutical sector.

Financial Trend Analysis

The financial trend for Lupin Ltd. remains positive as of 30 September 2026. The company has delivered healthy long-term growth, with net sales increasing at an annualised rate of 13.51% and operating profit growing at an even stronger 29.96%. The latest nine-month results show net sales of ₹22,919.07 crores, up 29.46%, and a profit after tax (PAT) of ₹4,481.79 crores, reflecting a remarkable 57.44% growth. These figures demonstrate Lupin’s ability to expand its top and bottom lines consistently, supported by strong operational execution and market demand.

Technical Outlook

From a technical standpoint, Lupin Ltd. currently holds a bearish grade. The stock has experienced downward pressure over recent months, with returns of -6.07% over the past month and -15.58% over the last three months. The one-year return remains positive at 6.95%, outperforming the broader BSE500 index, which has declined by 2.82% over the same period. However, the recent negative momentum suggests caution for short-term traders, as the stock faces resistance levels and market volatility.

Stock Performance and Market Context

As of 30 September 2026, Lupin Ltd. has delivered mixed returns across various time frames. The stock declined by 0.83% on the day, with weekly and monthly returns at -2.71% and -6.07% respectively. Despite this short-term weakness, the stock’s year-to-date (YTD) return is -3.27%, and it has generated a positive 6.95% return over the past year. This performance is notable given the challenging market environment, where the broader BSE500 index has posted negative returns. Institutional investors hold a significant 47.07% stake in Lupin, reflecting confidence from knowledgeable market participants who typically conduct thorough fundamental analysis.

Implications for Investors

The 'Hold' rating suggests that Lupin Ltd. is a stock to monitor closely rather than aggressively accumulate or divest. Investors should appreciate the company’s strong fundamentals and attractive valuation, which provide a solid foundation for long-term investment. However, the bearish technical signals and recent price volatility imply that the stock may face near-term headwinds. For those with a medium to long-term horizon, Lupin’s consistent earnings growth and healthy financial position offer reassurance, while more cautious investors may prefer to wait for clearer technical confirmation before increasing exposure.

Summary of Key Metrics as of 30 September 2026

• Mojo Score: 53.0 (Hold grade)
• Market Capitalisation: Midcap
• Debt to Equity Ratio: 0.11 times
• Net Sales Growth (Annualised): 13.51%
• Operating Profit Growth (Annualised): 29.96%
• PAT Growth (9M): 57.44% to ₹4,481.79 crores
• Net Sales (9M): ₹22,919.07 crores, up 29.46%
• ROCE (Half Year): 27.06%
• ROE: 25.7%
• Price to Book Value: 4.2
• PEG Ratio: 0.3
• Institutional Holdings: 47.07%
• 1-Year Stock Return: +6.95%
• BSE500 1-Year Return: -2.82%

Sector and Industry Context

Lupin Ltd. operates within the Pharmaceuticals & Biotechnology sector, a space characterised by innovation, regulatory challenges, and evolving market dynamics. The company’s ability to sustain growth amid these conditions is reflected in its strong financial metrics and consistent quarterly performance. The pharmaceutical sector often rewards companies with robust research pipelines and efficient cost management, both of which Lupin appears to manage well. Investors should consider sector trends alongside company-specific factors when evaluating Lupin’s prospects.

Conclusion

In summary, Lupin Ltd.’s current 'Hold' rating by MarketsMOJO reflects a nuanced view of the stock’s investment merits. The company’s strong quality and financial trends, combined with very attractive valuation metrics, provide a solid foundation for investors. However, the bearish technical outlook and recent price softness counsel prudence in the near term. Investors with a long-term perspective may find Lupin’s fundamentals compelling, while those focused on short-term price action might await clearer signals before committing further capital. This balanced approach aligns with the 'Hold' recommendation, signalling neither a strong buy nor a sell, but rather a measured stance based on current data as of 30 September 2026.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today